FDA Proposes Ditching 23 Archaic Food Identity Rules
Published Date: 7/17/2025
Proposed Rule
Summary
The FDA wants to get rid of 23 old food rules that aren’t really needed anymore to keep things honest for shoppers. This change will make life easier for food makers by cutting down on extra paperwork. If approved, these updates could save time and money without hurting what’s in your food.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Revokes 23 Food Identity Rules
The FDA is proposing to revoke 23 standards of identity for foods. This would reduce redundant regulatory requirements and make life easier for food makers by cutting down on extra paperwork, which the FDA says could save time and money for producers.
FDA Says Consumers Won’t Be Harmed
The FDA tentatively concludes the 23 standards are no longer necessary to promote honesty and fair dealing for consumers and says revoking them would not hurt what’s in your food. If finalized, the agency expects these changes would not reduce consumer protections related to food identity.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-13385 — Mental Health Service Professional Demonstration Grant Program
The Department of Education is updating rules for a grant program that helps schools hire more mental health pros like school psychologists, especially in places that really need them. These new rules will start with grant competitions in 2025 and aim to fix shortages in school mental health services. If you’re a school or group applying for these grants, watch for changes that could affect how and when you apply.
Next: 2025-13423 — Revocation of Food Standards for 11 Products Not Currently Sold
The FDA is planning to cancel 11 food rules for products that aren’t sold anymore in the U.S. This change helps clear out old, unnecessary rules so businesses and consumers can enjoy a simpler food system. If this goes through, it won’t cost anyone extra and will make things easier for food makers and shoppers alike.